SCHEMBL15051573

SCHEMBL15051573

COc1ccccc1-c1nn(-c2cc(NC(C)=O)ncc2C)cc1-c1nc[nH]n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.42
ADORA2A P29274 4/20 0.41
HSD17B10 Q99714 3/20 0.40
ALOX15 P16050 1/20 0.40
ADORA2B P29275 2/20 0.39
FYN P06241 2/20 0.37
PIK3CD O00329 1/20 0.37
PIK3CG P48736 1/20 0.37
RAB9A P51151 2/20 0.37
POLB P06746 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
AHR P35869 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ADORA1 P30542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15051877 0.91 ABL1 (0.36) ADORA3HSD17B10RAB9ANPC1ALDH1A1
SCHEMBL15050840 0.89 ABL1 (0.36) TDP1HPGDSMN1; SMN2ABL1
SCHEMBL15051589 0.88 NPC1 (0.32) ADORA3HSD17B10RAB9ATDP1HPGD
SCHEMBL15051323 0.86 PIK3CA (0.37) HSD17B10RAB9ATDP1KDM4ENPC1
SCHEMBL15051698 0.86 AR (0.35) RAB9ANPC1SMN1; SMN2LRRK2ABL1
SCHEMBL15051295 0.85 RAB9A (0.35) ADORA3FYNRAB9APOLBTDP1
SCHEMBL15051606 0.84 NPC1 (0.32) ADORA3RAB9ANPC1SMN1; SMN2ABL1
SCHEMBL15051313 0.84 ABL1 (0.40) RAB9ANPC1ALDH1A1SMN1; SMN2CDK9
SCHEMBL15072383 0.82 MAPK1 (0.36) HSD17B10TDP1HPGDKDM4ENPC1
SCHEMBL15051168 0.81 ABL1 (0.34) PIK3CGRAB9ANPC1SMN1; SMN2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 ADORA3 2319/4885ADORA2A 2938/4885HSD17B10 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.